美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lunai Bioworks

1.25

-0.0500-3.85%

盤後：1.20-0.0485-3.88%19:44 EST

成交量：21.23萬

成交額：26.55萬

市值：2,928.83萬

市盈率：-0.17

高：1.29

開：1.28

低：1.20

收：1.30

52周最高：21.00

52周最低：0.8100

股本：2,343.07萬

流通股本：1,500.00萬

量比：0.40

換手率：1.42%

股息：- -

股息率：- -

每股收益(TTM):-7.2217

每股收益(LYR):-10.7843

淨資產收益率：-308.01%

總資產收益率：-14.85%

市淨率：-2.25

市盈率(LYR):-0.12

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Lunai Bioworks

交易所：

NASDAQ

成立時間：

- -

員工人數：

29

公司地址：

2080 Century Park East,Suite 906,Los Angeles,California,United States

官網：

http://www.renovarogroup.com

郵編：

90067

電話：

傳真：

- -

簡介：

Lunai Bioworks Inc.於2011年1月18日在特拉華州註冊成立，通過三家子公司運營：Renovaro Biosciences、Renovaro Cube和BioSymetrics。Renovaro Cube，包括GediCube Intl。Ltd.及其子公司，於2024年2月13日被收購，而BioSymetrics及其子公司於2025年4月8日被收購。Renovaro Biosciences是該公司的生物技術部門，研究重點是開發旨在加強免疫反應的同種異體細胞和基因療法，旨在支持長期癌症緩解。繼收購GediCube INTL.后，Lunai越來越強調分子診斷和腫瘤技術。該公司的發展領域包括針對胰腺癌、肝癌、三陰性乳腺癌、頭頸癌等實體瘤的創新治療性疫苗接種平台。它的方法利用工程化供體細胞和分子診斷技術，有可能提供“現成的”治療方案，減少診斷和治療之間的延遲。

董事

名稱

職位

David Weinstein

Director and Chief Executive Officer

Douglas W. Calder

Director

James A. McNulty

Director

Mark A. Collins

Director

股東

名稱

職位

David Weinstein

Director and Chief Executive Officer

Nathen Fuentes

Chief Financial Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LNAI/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LNAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":1.25,"timestamp":1764968400000,"preClose":1.3,"halted":0,"volume":212308,"hourTrading":{"tag":"盘后","latestPrice":1.2015,"preClose":1.25,"latestTime":"19:44 EST","volume":19661,"amount":23842.5812,"timestamp":1764981849874},"delay":0,"floatShares":15000000,"shares":23430653,"eps":-7.221734,"marketStatus":"休市中","change":-0.05,"latestTime":"12-05 16:00:00 EST","open":1.28,"high":1.2899,"low":1.2,"amount":265539.666378,"amplitude":0.069154,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.221734,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.2098,"preClose":1.3,"latestTime":"08:54 EST","volume":5519,"amount":6797.1545923,"timestamp":1764942899153},"postHourTrading":{"tag":"盘后","latestPrice":1.2015,"preClose":1.25,"latestTime":"19:44 EST","volume":19661,"amount":23842.5812,"timestamp":1764981849874},"volumeRatio":0.39743747654918254,"impliedVol":1.4337,"impliedVolPercentile":0.4667},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","floatShares":15000000,"roa":"-14.85%","roe":"-308.01%","lyrEps":-10.784282,"volumeRatio":0.39743747654918254,"shares":23430653,"dividePrice":0,"high":1.2899,"amplitude":0.069154,"preClose":1.3,"low":1.2,"week52Low":0.81,"pbRate":"-2.25","week52High":21,"institutionHeld":0,"latestPrice":1.25,"eps":-7.221734,"divideRate":0,"volume":212308,"delay":0,"ttmEps":-7.221734,"open":1.28,"prevYearClose":8.355,"prevWeekClose":1.18,"prevMonthClose":1.18,"prevQuarterClose":1.42,"fiveDayClose":1.18,"twentyDayClose":1.02,"sixtyDayClose":2.006},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LNAI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"LNAI","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2025-09-30","symbol":"LNAI","defaultRemindTime":1759239000000,"type":"split","dateTimestamp":1759204800000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-09-29","symbol":"LNAI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1759118400000,"reportTimeType":"","actualEps":-0.76},{"market":"US","date":"2025-05-15","symbol":"LNAI","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2025-02-19","symbol":"LNAI","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1739941200000,"reportTimeType":"post","actualEps":-0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LNAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LNAI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LNAI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LNAI","date":"2025-12-05","current":-0.173089,"percent":0.066667,"low":-0.265446,"twenty":-0.211108,"median":-0.158218,"eighty":-0.130221,"high":-0.108594,"avg":-0.163761,"sd":0.041225,"marketCap":30462108},"quantilePoints":[{"date":"2025-10-03","current":-0.160171,"twenty":-0.164877,"median":-0.163112,"eighty":-0.161348,"marketCap":28511703},{"date":"2025-10-10","current":-0.161474,"twenty":-0.165919,"median":-0.164078,"eighty":-0.161474,"marketCap":28743506},{"date":"2025-10-17","current":-0.158869,"twenty":-0.16512,"median":-0.161474,"eighty":-0.158869,"marketCap":28279901},{"date":"2025-10-24","current":-0.135429,"twenty":-0.16512,"median":-0.160171,"eighty":-0.152098,"marketCap":24107456},{"date":"2025-10-31","current":-0.122514,"twenty":-0.163557,"median":-0.158218,"eighty":-0.135687,"marketCap":21808324},{"date":"2025-11-07","current":-0.132813,"twenty":-0.161474,"median":-0.152344,"eighty":-0.130739,"marketCap":23641716},{"date":"2025-11-14","current":-0.134115,"twenty":-0.161474,"median":-0.143888,"eighty":-0.121701,"marketCap":23873497},{"date":"2025-11-21","current":-0.254829,"twenty":-0.163557,"median":-0.147149,"eighty":-0.123011,"marketCap":33376540},{"date":"2025-11-28","current":-0.211108,"twenty":-0.166054,"median":-0.152344,"eighty":-0.125001,"marketCap":27650221},{"date":"2025-12-05","current":-0.232577,"twenty":-0.211108,"median":-0.158218,"eighty":-0.130221,"marketCap":30462108}],"updateTime":1765110272013},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":549849556,"employeeNum":29,"address":"2080 Century Park East,Suite 906,Los Angeles,California,United States","zipCode":"90067","officePhone":"305 918 1980"},"stockCompanyDetail":{"websiteUrl":"http://www.renovarogroup.com","stockEarnings":[{"period":"1week","weight":0.0593},{"period":"1month","weight":0.0684},{"period":"3month","weight":-0.3947},{"period":"6month","weight":-0.5953},{"period":"1year","weight":-0.9132},{"period":"ytd","weight":-0.8504}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Lunai Bioworks Inc.於2011年1月18日在特拉華州註冊成立，通過三家子公司運營：Renovaro Biosciences、Renovaro Cube和BioSymetrics。Renovaro Cube，包括GediCube Intl。Ltd.及其子公司，於2024年2月13日被收購，而BioSymetrics及其子公司於2025年4月8日被收購。Renovaro Biosciences是該公司的生物技術部門，研究重點是開發旨在加強免疫反應的同種異體細胞和基因療法，旨在支持長期癌症緩解。繼收購GediCube INTL.后，Lunai越來越強調分子診斷和腫瘤技術。該公司的發展領域包括針對胰腺癌、肝癌、三陰性乳腺癌、頭頸癌等實體瘤的創新治療性疫苗接種平台。它的方法利用工程化供體細胞和分子診斷技術，有可能提供“現成的”治療方案，減少診斷和治療之間的延遲。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.03245},{"month":2,"riseRate":0.428571,"avgChangeRate":0.007158},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.077517},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.083247},{"month":5,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":6,"riseRate":0.375,"avgChangeRate":-0.147122},{"month":7,"riseRate":0.625,"avgChangeRate":-0.018947},{"month":8,"riseRate":0.625,"avgChangeRate":0.533577},{"month":9,"riseRate":0.375,"avgChangeRate":-0.022213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035033},{"month":11,"riseRate":0.75,"avgChangeRate":0.142505},{"month":12,"riseRate":0.5,"avgChangeRate":-0.081546}],"exchange":"NASDAQ","name":"Lunai Bioworks","nameEN":"Lunai Bioworks"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LNAI\",market:\"US\",,,undefined,":{"directors":[{"name":"David Weinstein","position":"Director and Chief Executive Officer"},{"name":"Douglas W. Calder","position":"Director"},{"name":"James A. McNulty","position":"Director"},{"name":"Mark A. Collins","position":"Director"}],"executives":[{"name":"David Weinstein","position":"Director and Chief Executive Officer"},{"name":"Nathen Fuentes","position":"Chief Financial Officer"}]}}}